Back to Search
Start Over
Additional file 3 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
- Publication Year :
- 2022
- Publisher :
- figshare, 2022.
-
Abstract
- Additional file 3. Forest plot for comparing Arylia versus Prolia® in terms of mean percent changes in BMD of the lumbar spine (L1-L4), total hip, and femoral neck in 18 months duration of the study. Forest plot demonstrating both t-test analysis and ANCOVA model for ITT set.
- Subjects :
- musculoskeletal diseases
Subjects
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....0d2a206fd7809e22e0f07e52ba206463
- Full Text :
- https://doi.org/10.6084/m9.figshare.20206433